knowledge -WSS

knowledge

author：leisure time 2025-10-01 17:33:54 - browse：7548

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： 10 million people disenrolled from Medicaid over past six months

Wikipedia

WSS

Victims of gun violence feel impacts long after bullet wound

Medicare will require more price transparency from hospitals

Why 40% Americans with Parkinson’s don’t see a neurologist

Leqembi, other new Alzheimer’s drugs require better biomarkers

MoonLake credibility takes another hit with mid

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

hotspot

knowledge

focus

Moonlake's readout produced a cash windfall. Risks remain

Oak trusses raised to roof of fire

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Victims of gun violence feel impacts long after bullet wound

Anesthesiologist group: stop taking Ozempic before surgery

Sanofi CEO defends move to abandon profit guidance, boost research

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biden launches a new push to limit health care costs

Heart attack and stroke risk calculators need revising

MoonLake credibility takes another hit with mid

entertainment

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Iowa House, Senate pass 6

Victims of gun violence feel impacts long after bullet wound

Abortion clinic in Cancun will cater to Americans

The Sacklers, horror, and ‘The Fall of the House of Usher’

Sanofi CEO defends move to abandon profit guidance, boost research

knowledge

Wikipedia

leisure time

hotspot